Nancy Lin, MD

Articles

Evolving Treatment Landscape of HER2+ Metastatic Breast Cancer

March 10th 2022

Closing out their discussion on novel therapies for HER2+ metastatic breast cancer, experts share excitement for future clinical trials and strategies.

Treatment Options for HER2+, ER+ Metastatic Breast Cancer

March 2nd 2022

A panel of experts briefly reviews the treatment options available for patients with ER+, HER2+ metastatic breast cancer.

Special HER2+ mBC Populations: HR+ or HER2-Low Patients

March 2nd 2022

Expert panelists discuss the optimal management patients with special subsets of HER2+ metastatic breast cancer, such as HR+ or HER2-low disease.

Potential Role of Surgery in HER2+ Metastatic Breast Cancer

February 23rd 2022

Shared insight on the potential role for surgery in the setting of HER2+ metastatic breast cancer in the context of pharmacologic therapy.

SABCS 2021: Small Molecule Clinical Trials in R/R HER2+ mBC

February 23rd 2022

Rounding out their conversation on SABCS 2021, experts discuss small molecule–based treatment strategies for relapsed/refractory HER2+ metastatic breast cancer.

SABCS 2021: Combination Strategies Under Investigation for R/R HER2+ mBC

February 16th 2022

Considering data from the SABCS 2021 annual meeting, experts discuss novel combination strategies for relapsed/refractory HER2+ metastatic breast cancer.

HER2+ Breast Cancer: Updates on HER2CLIMB and CNS Disease Management

February 16th 2022

A brief review of updated data from HER2CLIMB and discussion on which agents may be best for treating patients with CNS disease.

Novel Treatment Approaches to R/R HER2+ Metastatic Breast Cancer

February 9th 2022

Experts discuss the role of novel therapies in relapsed/refractory HER2+ metastatic breast cancer accounting for results from recent clinical trial.

HER2+ mBC: Impact of T-DM1 and T-DXd Beyond the Frontline Setting

February 9th 2022

Shared insight on the roles of trastuzumab emtansine and trastuzumab deruxtecan in relapsed/refractory HER2+ metastatic breast cancer.

Monitoring Patients With HER2+ Metastatic Breast Cancer

February 2nd 2022

A brief review of patient monitoring and screening practices in the setting of HER2+ metastatic breast cancer.

Patient Case: Frontline Treatment Options for HER2+ mBC

February 2nd 2022

Taking into account a patient case of HER2+ metastatic breast cancer, experts review current frontline treatment options.

Patient Case: Biomarker Testing in Breast Cancer

January 26th 2022

Centered on a patient presentation of breast cancer, panelists consider optimal biomarker testing strategies to inform their treatment approach.

An Overview on the Current State of Metastatic Breast Cancer

January 26th 2022

Expert perspectives on the current treatment landscape of metastatic breast cancer and the unmet needs prevalent across various subsets of disease.

Dr. Lin on the Emergence of CAR T-Cell Therapy in Multiple Myeloma

January 7th 2021

Yi Lin, MD, PhD, discusses the emergence of CAR T-cell therapy in multiple myeloma.

Dr. Lin on the Treatment Landscape in HER2+ Metastatic Breast Cancer

July 16th 2020

Nancy U. Lin, MD, discusses the treatment landscape in HER2-positive metastatic breast cancer. 

Dr. Lin on CNS-Specific Outcomes With Neratinib in HER2+ Breast Cancer

February 12th 2020

Nancy Lin, MD, discusses central nervous system–specific outcomes with neratinib (Nerlyx) in HER2-positive breast cancer.

Dr. Lin on Impact of Neratinib on CNS Metastases in HER2+ Breast Cancer

December 13th 2019

Nancy Lin, MD, discusses the impact of neratinib on development and progression of central nervous system metastases in patients with HER2-positive metastatic breast cancer.